Big Pharma Split Corp Class A (PRM) — Capital Reinvestment Ratio
Big Pharma Split Corp Class A (PRM) has a Capital Reinvestment Ratio of 0.00x as of December 2023, meaning it reinvests 0% of its operating cash flow (CA$11.86 Million) in capital expenditures (CA$3.00). See PRM equity to assets ratio to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Big Pharma Split Corp Class A Capital Reinvestment Ratio (2020–2023)
This chart tracks Big Pharma Split Corp Class A's Capital Reinvestment Ratio across 2 annual periods. Check PRM cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Big Pharma Split Corp Class A (2020–2023)
Year-by-year Capital Reinvestment Ratio for Big Pharma Split Corp Class A from 2020 to 2023. For live market cap and broader valuation context, see PRM market cap overview.
| Year | Reinvestment Ratio | Operating CF (CAD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2023 | 0.00x | CA$11.86 Million | CA$3.00 | ▼ -63.3% |
| 2020 | 0.00x | CA$4.35 Million | CA$3.00 | — |